DNA - Ginkgo Bioworks Holdings, Inc. Stock Price, Fair Value and News

0.78USD-0.07 (-8.24%)Market Closed

Market Summary

USD0.78-0.07

Market Closed

-8.24%

DNA Stock Price

View Fullscreen

DNA RSI Chart

DNA Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-1.91

Price/Sales (Trailing)

6.77

EV/EBITDA

-0.92

Price/Free Cashflow

-5.06

DNA Price/Sales (Trailing)

DNA Profitability

EBT Margin

-355.11%

Return on Equity

-81.38%

Return on Assets

-53.61%

Free Cashflow Yield

-19.77%

DNA Fundamentals

DNA Revenue

Revenue (TTM)

251.5M

Rev. Growth (Yr)

-64.64%

Rev. Growth (Qtr)

-37.3%

DNA Earnings

Earnings (TTM)

-892.9M

Earnings Growth (Yr)

-20.65%

Earnings Growth (Qtr)

30.11%

Breaking Down DNA Revenue

Last 7 days

-3.4%

Last 30 days

-22.9%

Last 90 days

-33.3%

Trailing 12 Months

-30.6%

How does DNA drawdown profile look like?

DNA Financial Health

Current Ratio

6.11

DNA Investor Care

Shares Dilution (1Y)

5.78%

Diluted EPS (TTM)

-0.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	390.0M	326.0M	315.0M	251.5M
2022	438.1M	539.1M	527.9M	477.7M
2021	136.0M	195.2M	254.5M	313.8M
2020	0	0	65.4M	76.7M
2019	0	0	0	54.2M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Ginkgo Bioworks Holdings, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 02, 2024	dmytruk mark e.	sold	-53,727	1.05	-51,169	see remarks
Apr 01, 2024	dmytruk mark e.	acquired	-	-	108,123	see remarks
Mar 04, 2024	dmytruk mark e.	sold	-48,765	1.256	-38,826	see remarks
Mar 01, 2024	dmytruk mark e.	acquired	-	-	85,214	see remarks
Feb 02, 2024	dmytruk mark e.	sold	-47,799	1.208	-39,569	see remarks
Feb 01, 2024	dmytruk mark e.	acquired	-	-	85,208	see remarks
Jan 04, 2024	kelly jason r	sold	-155,500	1.555	-100,000	see remarks
Jan 03, 2024	dmytruk mark e.	sold	-70,522	1.54	-45,794	see remarks
Jan 03, 2024	kelly jason r	sold	-154,400	1.544	-100,000	see remarks
Jan 02, 2024	dmytruk mark e.	acquired	-	-	85,048	see remarks

Which funds bought or sold DNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	added	1.35	-20,000	44,000	-%
Apr 24, 2024	BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC	unchanged	-	-159	348	-%
Apr 24, 2024	Simplicity Wealth,LLC	new	-	12,960	12,960	-%
Apr 24, 2024	Carmichael Hill & Associates, Inc.	unchanged	-	-63.00	140	-%
Apr 24, 2024	Spire Wealth Management	reduced	-59.65	-11,031	6,960	-%
Apr 24, 2024	Activest Wealth Management	unchanged	-	-822	1,799	-%
Apr 24, 2024	BROWN ADVISORY INC	reduced	-1.06	-129,840	274,788	-%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	added	600	12,860	16,240	0.01%
Apr 23, 2024	Strategic Blueprint, LLC	unchanged	-	-5,300	11,600	-%
Apr 23, 2024	CIGNA INVESTMENTS INC /NEW	unchanged	-	-7,000	18,000	-%

Are Funds Buying or Selling DNA?

Are funds buying DNA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DNA

No. of Funds

Unveiling Ginkgo Bioworks Holdings, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	knight thomas f. jr.	4.1%	68,328,434	SC 13G/A
Feb 14, 2024	che austin	5.6%	95,898,483	SC 13G/A
Feb 14, 2024	shetty reshma p.	10.5%	188,643,922	SC 13D/A
Feb 14, 2024	kelly jason r	5.0%	85,752,333	SC 13D/A
Feb 14, 2024	viking global investors lp	8.8%	143,085,126	SC 13G/A
Feb 13, 2024	vanguard group inc	8.20%	132,779,676	SC 13G/A
Jan 29, 2024	ark investment management llc	12.26%	198,606,619	SC 13G/A
Jan 29, 2024	baillie gifford & co	14.59%	236,292,183	SC 13G/A
Feb 14, 2023	anchorage capital group, l.l.c.	4.83%	69,904,593	SC 13G/A
Feb 14, 2023	che austin	6.3%	99,857,282	SC 13G/A

Recent SEC filings of Ginkgo Bioworks Holdings, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 24, 2024	144	Notice of Insider Sale Intent
Apr 23, 2024	144	Notice of Insider Sale Intent
Apr 22, 2024	144	Notice of Insider Sale Intent
Apr 19, 2024	144	Notice of Insider Sale Intent
Apr 18, 2024	144	Notice of Insider Sale Intent
Apr 17, 2024	144	Notice of Insider Sale Intent
Apr 16, 2024	144	Notice of Insider Sale Intent
Apr 15, 2024	144	Notice of Insider Sale Intent
Apr 12, 2024	144	Notice of Insider Sale Intent
Apr 11, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Ginkgo Bioworks Holdings, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.39%	-19.31%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	5.41%	-4.57%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.99%	-29.65%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-4.67%	-6.03%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-13.72%	-45.61%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-0.25%	294.45%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.06%	3.25%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	70.91%	57.98%	-0.22	2.14	-13.45%	66.37%

Ginkgo Bioworks Holdings, Inc. News

Latest updates

Ginkgo Bioworks Holdings, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Revenue	-37.3%	34,755,000	55,430,000	80,568,000	80,702,000	98,285,000	66,398,000	144,618,000	168,405,000	148,494,000	77,610,000	43,636,000	44,097,000	28,699,500	13,302,000	-
Operating Expenses	-37.7%	212,872,000	341,823,000	264,719,000	296,447,000	329,149,000	721,336,000	792,397,000	843,776,000	1,833,229,000	104,282,000	103,581,000	101,212,000	-	47,715,000	-
S&GA Expenses	8.8%	89,223,000	82,028,000	102,341,000	111,433,000	121,383,000	435,221,000	438,427,000	434,768,000	781,626,000	28,959,000	34,440,000	17,927,000	5,000	9,876,000	-
R&D Expenses	-100.0%	-	156,662,000	144,282,000	162,639,000	177,548,000	261,460,000	290,059,000	323,576,000	985,025,000	53,021,000	52,031,000	59,585,000	-	36,070,000	-
EBITDA Margin	-35.5%	-3.27	-2.41	-3.52	-4.27	-4.35	-6.61	-5.44	-5.30	-5.76	-1.29	-1.36	-1.04	-1.42	-1.50	-1.97
Interest Expenses	-391.8%	-43,821,000	15,020,000	14,349,000	14,545,000	-8,538,000	6,380,000	2,264,000	-177,000	3,854,000	-528,000	-478,000	-475,000	-	8,293,000	-
Income Taxes	-800.0%	-198,000	-22,000	67,000	82,000	-14,770,000	-28,000	-45,000	-184,000	-683,000	-207,000	-431,000	-159,000	-	6,000	-
Earnings Before Taxes	30.0%	-211,892,000	-302,913,000	-173,248,000	-204,887,000	-187,848,000	-670,159,000	-670,615,000	-592,777,000	-1,605,678,000	-102,612,000	-54,895,000	-74,937,000	-	-26,120,000	-
EBT Margin	-28.7%	-3.55	-2.76	-3.79	-4.44	-4.44	-6.70	-5.51	-5.38	-5.86	-1.41	-1.52	-1.19	-1.63	-1.69	-2.21
Net Income	30.1%	-211,694,000	-302,891,000	-173,315,000	-204,969,000	-175,468,000	-670,131,000	-668,825,000	-590,505,000	-1,600,656,000	-101,881,000	-53,941,000	-73,569,000	-5,000	-26,055,000	-
Net Income Margin	-30.6%	-3.55	-2.72	-3.75	-4.41	-4.41	-6.69	-5.49	-5.36	-5.83	-1.16	-1.15	-1.22	-1.05	-1.68	-2.20
Free Cashflow	21.4%	-61,277,000	-77,932,000	-87,066,000	-110,026,000	-130,176,000	-41,834,000	-108,981,000	-23,478,000	-170,655,000	-10,673,000	-58,945,000	-70,066,000	-19,413,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-17.8%	1,665	2,026	2,292	2,417	2,539	1,871	1,994	2,058	2,071	2,151	1,726	1,728	675	697
Current Assets	-12.3%	1,002	1,142	1,223	1,327	1,450	1,462	1,599	1,706	1,723	1,811	1.00	3.00	427	512
Cash Equivalents	-10.0%	944	1,049	1,106	1,206	1,316	1,303	1,377	1,493	1,550	1,739	236	308	381	495
Inventory	-100.0%	-	0.00	0.00	3.00	4.00	6.00	8.00	9.00	3.00	3.00	-	-	3.00	-
Net PPE	-6.6%	188	202	294	314	315	188	176	149	146	143	-	-	121	63.00
Goodwill	-15.2%	49.00	58.00	59.00	59.00	60.00	29.00	31.00	21.00	21.00	17.00	-	-	2.00	2.00
Liabilities	-26.6%	568	774	788	810	803	431	427	444	504	533	255	150	205	195
Current Liabilities	-2.7%	164	168	163	192	173	125	135	159	135	90.00	5.00	1.00	73.00	40.00
Shareholder's Equity	-12.4%	1,097	1,253	1,504	1,608	1,736	1,444	1,572	1,619	1,567	1,618	356	396	470	502
Retained Earnings	-4.2%	-5,290	-5,078	-4,775	-4,602	-4,397	-4,222	-3,557	-2,888	-2,297	-697	-101	5.00	-467	-341
Additional Paid-In Capital	0.8%	6,386	6,334	6,281	6,212	6,136	5,669	5,098	4,471	3,805	2,250	106	-	929	-
Shares Outstanding	1.4%	2,001	1,973	1,924	-	1,892	1,631	1,621	1,607	1,360	1,302	1,291	1,290	1,275	1,149
Minority Interest	-	-	-	-	-	-	5.00	32.00	33.00	62.00	66.00	-	-	9.00	9.00
Float	-	-	-	2,433	-	-	-	2,392	-	-	-	251	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	21.4%	-57.83	-73.55	-73.53	-90.58	-104	-28.36	-99.41	-19.90	-165	-5.23	-34.91	-48.13	-	-	-
Share Based Compensation	-18.5%	43.00	53.00	61.00	73.00	108	563	607	653	-	0.00	15.00	0.00	-	-	-
Cashflow From Investing	-1280.5%	-46.67	-3.38	-11.22	-19.41	30.00	-46.49	-14.66	-35.98	4.00	-30.51	-23.93	-23.05	-	-	-
Cashflow From Financing	-100.6%	-0.63	-0.31	-1.38	-0.89	98.00	-0.39	-0.84	-1.19	-11.04	1,548	-2.12	-0.43	-	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	25.00	-	-	-	-	-

DNA Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Biosecurity revenue:

Total revenue

$ 251,455

$ 477,706

$ 313,837

Costs and operating expenses:

Research and development

580,621

1,052,643

1,149,662

General and administrative

385,025

1,429,799

862,952

Impairment of lease assets

96,210

Total operating expenses

1,115,861

2,686,658

2,142,304

Loss from operations

(864,406)

(2,208,952)

(1,828,467)

Other income (expense):

Interest income

57,217

20,262

837

Interest expense

(93)

(106)

(2,373)

Loss on equity method investments

(2,635)

(43,761)

(77,284)

Loss on investments

(54,827)

(53,335)

(11,543)

Change in fair value of warrant liabilities

5,168

124,970

58,615

Gain on settlement of partnership agreement

23,826

(Loss) gain on deconsolidation of subsidiaries

(42,502)

31,889

Other income (expense), net

9,138

7,634

(1,733)

Total other income (expense), net

(28,534)

87,553

(9,655)

Loss before income taxes

(892,940)

(2,121,399)

(1,838,122)

Income tax benefit

(71)

(15,027)

(1,480)

Net loss

(892,869)

(2,106,372)

(1,836,642)

Loss attributable to non-controlling interest

(1,443)

(6,595)

Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders

$ (892,869)

$ (2,104,929)

$ (1,830,047)

Net loss per share attributable to Ginkgo Bioworks Holdings, Inc. common stockholders:

Basic (in dollars per share)

$ (0.46)

$ (1.25)

$ (1.35)

Diluted (in dollars per share)

$ (0.46)

$ (1.25)

$ (1.39)

Weighted average common shares outstanding:

Basic (in shares)

1,944,420,000

1,679,061,000

1,359,849,000

Diluted (in shares)

1,944,420,000

1,679,839,000

1,360,373,000

Comprehensive loss:

Net loss

$ (892,869)

$ (2,106,372)

$ (1,836,642)

Other comprehensive loss:

Foreign currency translation adjustment

4,116

(917)

(1,715)

Total other comprehensive gain (loss)

4,116

(917)

(1,715)

Comprehensive loss

(888,753)

(2,107,289)

(1,838,357)

Cell Engineering revenue

Biosecurity revenue:

Total revenue

^[1]

143,531

143,666

112,989

Product

Biosecurity revenue:

Total revenue

28,949

35,455

23,040

Costs and operating expenses:

Cost of Biosecurity product and service revenue

7,481

20,646

20,017

Service

Biosecurity revenue:

Total revenue

78,975

298,585

177,808

Costs and operating expenses:

Cost of Biosecurity product and service revenue

$ 46,524

$ 183,570

$ 109,673

[1]	Includes related party revenue of $22,222, $38,813, and $47,161 for the years ended December 31, 2023, 2022, and 2021, respectively.

DNA Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 944,073	$ 1,315,792
Accounts receivable, net	17,157	80,907
Accounts receivable - related parties	742	1,558
Prepaid expenses and other current assets	39,777	51,822
Total current assets	1,001,749	1,450,079
Property, plant and equipment, net	188,193	314,773
Operating lease right-of-use assets	206,801	400,762
Investments	78,565	112,188
Equity method investments	0	1,543
Intangible assets, net	82,741	111,041
Goodwill	49,238	60,210
Other non-current assets	58,055	88,725
Total assets	1,665,342	2,539,321
Current liabilities:
Accounts payable	9,323	10,451
Deferred revenue (includes $5,426 and $10,309 from related parties)	44,486	47,817
Accrued expenses and other current liabilities	110,051	114,694
Total current liabilities	163,860	172,962
Non-current liabilities:
Deferred revenue, net of current portion (includes $119,053 and $131,188 from related parties)	158,062	174,767
Operating lease liabilities, non-current	221,835	413,256
Warrant liabilities	5,700	10,868
Other non-current liabilities	18,733	31,191
Total liabilities	568,190	803,044
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 200,000 shares authorized; none issued	0	0
Common stock, $0.0001 par value (Note 12)	199	190
Additional paid-in capital	6,385,997	6,136,378
Accumulated deficit	(5,290,528)	(4,397,659)
Accumulated other comprehensive income (loss)	1,484	(2,632)
Total stockholders’ equity	1,097,152	1,736,277
Total liabilities and stockholders’ equity	$ 1,665,342	$ 2,539,321

About Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

CEO	Dr. Jason Kelly
WEBSITE	ginkgobioworks.com
INDUSTRY	Biotechnology
EMPLOYEES	1292

Ginkgo Bioworks Holdings, Inc. Frequently Asked Questions

What is the ticker symbol for Ginkgo Bioworks Holdings, Inc.? What does DNA stand for in stocks?

DNA is the stock ticker symbol of Ginkgo Bioworks Holdings, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ginkgo Bioworks Holdings, Inc. (DNA)?

As of Wed Apr 24 2024, market cap of Ginkgo Bioworks Holdings, Inc. is 1.7 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DNA stock?

You can check DNA's fair value in chart for subscribers.

What is the fair value of DNA stock?

You can check DNA's fair value in chart for subscribers. The fair value of Ginkgo Bioworks Holdings, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ginkgo Bioworks Holdings, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ginkgo Bioworks Holdings, Inc. a good stock to buy?

The fair value guage provides a quick view whether DNA is over valued or under valued. Whether Ginkgo Bioworks Holdings, Inc. is cheap or expensive depends on the assumptions which impact Ginkgo Bioworks Holdings, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DNA.

What is Ginkgo Bioworks Holdings, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, DNA's PE ratio (Price to Earnings) is -1.91 and Price to Sales (PS) ratio is 6.77. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DNA PE ratio will change depending on the future growth rate expectations of investors.